Leronlimab has a very narrow window for statistical significance. The trial will have to end up something like 19% mortality in the treatment arm and 29% in the placebo arm. It isn't likely but it is possible. Of course, that is assuming there are 87 total deaths but that is highly unlikely.
Market Data 
Markets 
AI
